Cambium Bio (ASX:CMB) Limited, a clinical-stage regenerative medicine company, has set out how it intends to fund and launch the Phase 3 trial of its lead product, Elate Ocular, in its September 2026 quarterly update. Central to the plan is a A$7.1 million (US$5.0 million) placement that remains conditional on a shareholder vote at the company's annual general meeting on 9 November 2026.

Cash and funding

Cambium finished the quarter to 30 September with A$1.194 million of cash, compared with A$1.104 million at 30 June. Net operating outflow was A$0.735 million, of which research and development accounted for A$0.506 million. Customer receipts were A$0.146 million, which the company attributes to royalties on its fibrinogen-depleted human platelet lysate cell culture supplement products. A July placement raised A$1.008 million, and the company repaid an unsecured senior note of A$0.158 million when it matured on 7 August.

Including an undrawn facility, the company reported total available funding of A$4.944 million and a runway of 6.73 quarters under the Appendix 4C calculation. Cambium cautioned that spending is expected to rise as the Phase 3 trial begins, so that runway will probably shorten, and the figure excludes the conditional placement.

The A$7.1 million placement covers 14,791,667 shares at A$0.48 for Zheng Yang Biomedical Technology and three individual investors. It needs shareholder approval at the 9 November meeting, requires all four tranches to be issued on the same day, and lapses if approval is not obtained by 30 November. The undrawn facility, worth A$3.75 million, is provided by Rockford RDF and secured over the company's expected FY2027 research and development tax incentive refund. It carries interest of 16 per cent a year compounding daily, a 1.25 per cent establishment fee, a minimum cash covenant of A$300,000 and an undertaking to raise at least A$4.0 million in equity after the 2026 AGM.

Regulatory and trial readiness

Cambium said that at a Type D meeting on 22 April 2026 the US Food and Drug Administration indicated that one adequate and well-controlled pivotal study plus confirmatory evidence is a reasonable basis for a biologics licence application. The scope of the confirmatory evidence will be discussed after topline data. An updated CAMOMILE-2 protocol and statistical analysis plan reached the FDA's biologics centre on 14 September and has been approved by ethics bodies in Australia and the United States. Elate Ocular already holds Fast Track status and orphan designation for dry eye disease secondary to chronic graft-versus-host disease.

Manufacturing and operations

Manufacturing is the next gating item. A technical batch using the Phase 3 process, including a UV-C pathogen inactivation step, was made in September and gamma irradiated in October. An engineering batch began on 19 October, and the first clinical batch is scheduled for November 2026. Release for the trial depends on testing and comparability with the engineering batch, and the company noted this is the first time the three-step process has been run at Phase 3 scale.

On the clinical side, master services and work agreements with the contract research organisation had not been signed when the update was released, and the target has slipped from the third to the fourth calendar quarter of 2026. Signing and initial payments are the main steps before sites in Australia and the United States can be activated.

Timeline and risks

The company's indicative timeline has first patient in by the end of calendar 2026, completion of enrolment in mid-2027, topline data in the fourth quarter of 2027, a rolling licence application submission in mid-2028 and a potential approval in late 2028 or early 2029.

Shareholders will vote on the placement and ratification of 2,000,000 options issued to the chief executive at the online meeting at 11:00am Sydney time on 9 November.